特写独家！坚果投影仪售后再遭质疑：保修期内收取花式费用引消费者不满

坚果投影仪售后再遭质疑：保修期内收取花式费用引消费者不满

北京，2024年6月15日 - 据黑猫投诉平台数据显示，今年5月，坚果投影仪在黑猫投诉平台上的投诉量位居日用电器行业前列，主要集中在售后服务问题方面。其中，有消费者投诉称，其在坚果投影仪官方售后服务中心维修投影仪时，被收取了多项不合理费用，包括检测费、人工费、配件费等。

一位消费者投诉称，其在京东自营店购买了一台坚果投影仪，使用不到一年就出现了画面闪烁问题。 联系坚果官方售后后，对方要求将投影仪寄回售后服务中心进行维修。然而，维修完成后，消费者却被收取了300元的检测费和人工费。

另一位消费者则投诉称，其在拼多多百亿补贴购买了一台坚果投影仪，收货后发现机器外壳有破损。 联系坚果官方售后后，对方表示可以提供维修服务，但需要消费者先支付更换外壳的费用。

针对上述投诉，坚果投影仪方面尚未作出回应。 不过，这并非坚果投影仪首次因售后服务问题而受到质疑。此前，就有消费者反映，坚果投影仪的售后服务态度差、维修效率低、配件价格虚高等问题。

业内人士指出，近年来，随着投影仪市场竞争的日趋激烈，一些投影仪厂商为了降低成本，在售后服务方面偷工减料。 这不仅损害了消费者的权益，也对投影仪行业整体形象造成了负面影响。

希望投影仪厂商能够重视售后服务，切实保障消费者的合法权益。 同时，消费者在购买投影仪时，也应选择信誉良好的品牌，并仔细阅读售后服务条款，避免自身权益受到侵害。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.